GF Group Holding
VC Fund
GF Group Holding is a VC fund focused on Biotechnology and Industrial. GF Group Holding engages in the fields of private equity, real estate and management manage asset operates.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries GF Group Holding invests in
Stages GF Group Holding invests in
Countries GF Group Holding invests in
Investment Focus
Industry
- Biotechnology 2 (40%)
- Industrial 1 (20%)
- Health Care 1 (20%)
- Collaboration 1 (20%)
- Manufacturing 1 (20%)
Stage
- Seed 1 (20%)
- Series B 1 (20%)
- Series C 1 (20%)
- Post-IPO Equity 1 (20%)
Country
- Switzerland 2 (40%)
- China 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Memo Therapeutics
|
Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis.Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’simmune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery.MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations. | $22M / Series C / May 07, 2024 | |
|
Memo Therapeutics
|
Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis.Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’simmune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery.MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations. | $27.6M / Series C / Nov 02, 2023 | |
|
Memo Therapeutics
|
Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis.Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’simmune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery.MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations. | $24.9M / Series B / Feb 16, 2022 | |
Jcet
|
JCET Group manufactures semiconductor products. | $777.3M / Post-IPO Equity / May 07, 2021 | |
Oncobit
|
Oncobit enabling personalized cancer care by developing precise and highly sensitive diagnostic and monitoring tests. | $2.5M / Seed / Apr 30, 2021 |
Co-Investors
Swisscanto Private Equity
4 deals together
Vesalius Biocapital Partners
4 deals together
Fresenius Medical Care
3 deals together
Verve Ventures
3 deals together
Adjuvant Capital
2 deals together
Pureos Bioventures
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does GF Group Holding invest in?
GF Group Holding invests primarily in Biotechnology, Industrial and Health Care startups, most often at Seed and Series B stage. Most of the 5 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did GF Group Holding last invest?
The most recent investment recorded for GF Group Holding closed in May 2024. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
